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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on the safety of dried whole cell Euglena gracilis
as a novel food (NF) pursuant to Regulation (EU) 2015/2283. E. gracilis is a single-cell microalga which
occurs widely in nature and is commonly found in freshwater habitats. The NF, the dried biomass of
E. gracilis, is produced by fermentation and its major constituent (> 50%) is a b-glucan
polysaccharide. The applicant proposed to use the NF in food supplements, in foods for total diet
replacement for weight control and as a food ingredient added to a number of food products. The
target population proposed by the applicant is the general population, except for food supplements
and for foods for total diet replacement for which the target population is the general population from
12 months of age onwards. In 2019, E. gracilis was attributed the qualified presumption of safety
(QPS)-status with the qualification ‘for production purposes only’, which includes food products based
on microbial biomass of the microalga. Based on the information provided, E. gracilis is not expected
to survive the manufacturing process. The submitted toxicity studies did not raise safety concerns. No
adverse effects were observed in the subchronic toxicity study, up to the highest dose tested, i.e.
3,300 mg NF/kg body weight, considered as the no observed adverse effect level (NOAEL). The
margins of exposure between this dose and the high (95th percentile) intake estimates, range from 33
for infants to 192 for adults. The Panel considers that in view of the QPS status of the source of the
NF, supported by the compositional data and lack of toxicity observed in the 90-day study, the margins
of exposure are sufficient. The Panel considers that the NF, i.e. dried whole cell Euglena gracilis, is safe
at the proposed uses and use levels.
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of European Food Safety Authority.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 20 December 2018, the company Kemin Foods L.C. submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) No 2015/22831 to place dried whole cell
Euglena on the European Union market as a novel food.
The novel food is proposed for use in a number of food categories and is intended for the general
population.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on dried whole cell Euglena.
Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on
novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council
and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and
Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following an EFSA request for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As
indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary,
confidential and published) scientific data, including both data in favour and not in favour to
supporting the safety of the proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise:
in vitro fermentation studies (Kemin Corporation, 2016), bacterial reverse mutation assay (Product
Safety Labs, 2015a), in vivo micronucleus test (Product Safety Labs, 2015b), acute toxicity study
(Product Safety Labs, 2014), 14-day toxicity/palatability study (Product Safety Labs, 2015c), 90-day
toxicity study (Product Safety Labs, 2015d).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use, and is not an assessment of the efficacy of the NF with regard to any
(claimed) benefit.
3. Assessment
3.1. Introduction
The NF that is the subject of the application is dried whole cell Euglena, which is the dried biomass
of the microalga Euglena gracilis.
The NF falls under Article 3(2)(a)(ii) foods consisting of, isolated from or produced from
microorganisms, fungi or algae, as defined in Regulation 2015/2283.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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The NF is produced by fermentation and its major constituent (> 50%) is a b-glucan
polysaccharide. The NF is proposed by the applicant to be used as a food supplement, in foods for
total diet replacement for weight control (as defined by Regulation (EU) 609/20133) and as a food
ingredient in a number of foods. The target population proposed by the applicant is the general
population, except for food supplements and for foods for total diet replacement for which the target
population is the general population from 12 months of age onwards.
3.2. Identity of the NF
The NF is dried whole cell Euglena, which is the dried biomass of Euglena gracilis.
E. gracilis is a single-cell microalga, belonging to the genus Euglena, which are phototrophic
euglenoid flagellates. E. gracilis occurs widely in nature and is commonly found in freshwater habitats,
especially in shallow eutrophic ponds.
E. gracilis can be cultivated under a variety of conditions including autotrophically with CO2 and
light as the sole source of carbon and energy, mixotrophically in light with an organic carbon source,
or heterotrophically in the dark with a carbon source (Krajcovic et al., 2015). The major energy
storage in E. gracilis is made through production of paramylon, a b-1,3-glucan, and wax esters.
Euglena can accumulate large amounts (i.e. up to 95% of the cell mass) of paramylon, a b-1,3-
polymer of glucose, when grown in the presence of adequate carbon sources under heterotrophic
growth conditions (Barsanti et al., 2011).
The specific strain used by the applicant is E. gracilis Klebs var. bacillaris ATCC (American Type
Culture Collection) PTA-123017. The identity was verified with three separate cultivation lots of the
algae. Identification was performed by amplifying specific gene regions via polymerase chain reaction
(PCR) and comparing these sequences to the HERBTM reference DNA-sequence database. The analyses
were conducted at an accredited laboratory and respective certificates of analysis were provided.
The full taxonomic classification of the employed strain is the following. Empire: Eukaryota;
Kingdom: Protozoa; Subkingdom: Eozoa; Phylum: Euglenozoa; Subphylum: Euglenoida; Class:
Euglenophyceae; Order: Euglenales; Family: Euglenaceae; Genus: Euglena; Species: Euglena gracilis
Klebs var. bacillaris; Strain: ATCC PTA-123017.
The strain is deposited in the ATCC Patent Depository and the certificate of deposit was provided by
the applicant.
Throughout the application dossier (including certificates of analysis and safety studies) various
names are used for the NF, i.e. ‘dried whole cell Euglena (WCE)’, ‘BetaViaTM Complete’ and ‘dried algae
(Euglena gracilis)’. The applicant confirmed that these denominations refer to the same food, i.e. the
NF that is the subject of this application.
3.3. Production process
According to the information provided, the NF is produced following current Good Manufacturing
Practices (cGMP) and Hazard Analysis Critical Control Points (HACCP) principles.
The parent cell line of the E. gracilis strain used for the manufacturing process is maintained on
agar plates stored in cool conditions in the dark. At regular intervals the algae are transferred to new
plates and, as needed, to shake flasks. The reason being that microalga, including E. gracilis, are
recalcitrant to cryogenic preservation (Day et al., 2007), and the most common procedure for
conservation of microalgal cultures is perpetual maintenance (i.e. continuous culture) under controlled
conditions (Lorenz et al., 2005).
For the manufacturing process of the NF, E. gracilis cells are transferred from the maintenance
culture to shake flasks of increasing size and, subsequently, to a production fermenter, which is
maintained at specified culture conditions (confidential information). A complete list of the culture
media and processing aids/additives plus the respective certificates of analysis were provided
(confidential information).
At the production fermenter scale, E. gracilis can be harvested daily. Since the process is
continuous, Euglena may be harvested at any time (usually when a certain cell density (confidential) is
3 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181,
29.6.2013, p. 35.
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achieved). The culture is harvested by filtration methods using appropriate food grade contact
materials to produce a concentrated slurry, which is then heated. After adjusting the pH of the slurry
with food grade NaOH it is pumped to a drum dryer, which dries the material into flakes. The flakes
are collected and subsequently milled, bagged (using appropriate food contact material) and stored
until shipment.
The applicant was requested to provide evidence/information to demonstrate that E. gracilis is
killed during the manufacturing process. In reply, the applicant reiterated that during the
manufacturing process, E. gracilis is heated to a certain temperature which is kept for a sufficient
amount of time (confidential information) to ensure that the microalgae cannot survive. To
substantiate this statement, the applicant provided a reference (Khanna and Yadav, 2004) that showed
that E. gracilis is killed after exposure to 44°C for 8 min. Furthermore, after the heat-inactivation step,
the Euglena slurry is adjusted to a high pH (above 8), at which, according to the literature (Danilov
and Ekelund, 2001), Euglena does not survive. Finally, the applicant emphasised that at the end of the
manufacturing process, the alkaline Euglena slurry is heated to a temperature above 100°C, which
would kill any potentially remaining viable Euglena cells.
The Panel considers that the microalga is not expected to survive the manufacturing process.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The major constituent of the NF is a b-glucan (a polymer of b-1,3-glucose), which constitutes at
least 50% of the NF on a dry weight basis. This linear unbranched polymer, produced as energy
storage polysaccharide by Euglena species, is also denominated as paramylon.
Paramylon is synthesised as a fibrillar high molecular weight polymer ( 500 kDa) with a high level
of crystallinity (up to 90%). It is deposited in the Euglena cells in the form of small discoid granules.
According to the literature, paramylon granules synthesised by E. gracilis are of high purity
corresponding to 100% glucose, as measured by nuclear magnetic resonance (NMR) (Barsanti et al.,
2011).
The applicant provided batch to batch testing for the content of b-glucan, organoleptic properties,
heavy metals and microbial counts for five batches of the NF (Table 1).
Table 1: Batch-to-batch analysis of the NF
Parameter
(unit)
Batch number Method of
analysis1801111503 1801111504 1801111505 1801111506 1801111509
Microscopic
identity
Conforms Conforms Conforms Conforms Conforms KHM-005-090
Appearance (free-
flowing powder)
Conforms Conforms Conforms Conforms Conforms KHM-005-916
Colour Yellow-tan Yellow-tan Yellow-tan Yellow-tan Yellow-tan KHM-005-916
Odour Charact. of
algae
Charact. of
algae
Charact. of
algae
Charact. of
algae
Charact. of
algae
KHM-005-916
b-glucan (%)(a) 61 62 61 61 64 AOAC 991.43
Heavy metals(b)
Lead (mg/kg) < 0.005 < 0.005 < 0.005 0.01 < 0.005 ICP-MS(c)
Cadmium (mg/kg) < 0.005 < 0.005 < 0.005 < 0.005 < 0.005 ICP-MS(c)
Mercury (mg/kg) < 0.005 < 0.005 < 0.005 < 0.005 < 0.005 ICP-MS(c)
Arsenic (mg/kg) < 0.02 < 0.01 < 0.01 < 0.01 < 0.01 ICP-MS(c)
Microbiological
Aerobic plate
count (CFU/g)
7,700 5,500 8,000 6,800 1,400 AOAC 966.23
Coliforms (MPN/g) < 3 < 3 < 3 < 3 < 3 FDA-BAM
Yeast and mould
(CFU/g)
70 40 20 20 20 FDA-BAM
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The applicant also provided proximate analyses for five additional batches of the NF. Total
carbohydrates ranged from 63.7% to 71.1%, of which total dietary fibre from 51.8% to 60.4%. The
protein content ranged from 17.8% to 23.2%, fat from 6.1% to 9.8%, ash from 3.3% to 5.1% and
moisture from 3.0% to 5.1%.
In addition to the proximates, the applicant provided detailed analyses of fatty acids, amino acids,
sugars, vitamins, minerals and carotenoids in the NF.
Furthermore, analyses were provided by the applicant for polycyclic aromatic hydrocarbons (PAHs)
and aflatoxins (B1, B2, G1, G2), which were all well below regulatory limits commonly used for other
foods (e.g. cereal-based foods).
The applicant also investigated the toxin-producing potential of E. gracilis, considering that two
other species, i.e. Euglena sanguinea and Euglena granulate (but not E. gracilis), from the same genus
have been reported to be able to produce toxic secondary metabolites (Zimba et al., 2004, 2010). The
applicant submitted a certificate of analysis for six samples of the NF which were all below the limit of
detection (LOD) (i.e. < 0.1 pg/g) for euglenophycin.
Information was provided on the accreditation of the laboratories that conducted the analyses
presented throughout the application.
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
3.4.1. Stability
The applicant provided information on stability testing, which was performed with four batches of
the NF for up to 26 months under ambient conditions (15–25°C) and with one batch of the NF under
accelerated conditions (40°C and 75% relative humidity) for up to 6 months.
The batches were analysed for moisture, protein and total dietary fibre content. In addition, the
content of total carbohydrates was provided under ambient conditions, while in the testing under
accelerated conditions also appearance and odour of the NF were evaluated.
There were no relevant changes in the parameters assessed at any time point. No changes in the
sensory evaluation were observed. Based on the data, the applicant proposed that the NF would be
stable when stored under ambient conditions in unopened, tightly sealed containers for a period of up
to 2 years.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF for up to 2 years under ambient conditions.
3.5. Specifications
The specifications for the organoleptic, physicochemical and microbiological parameters of the NF
are indicated in Table 2.
Parameter
(unit)
Batch number Method of
analysis1801111503 1801111504 1801111505 1801111506 1801111509
Escherichia coli
(in 10 g)
Absent Absent Absent Absent Absent USP
Staphylococcus
aureus (in 10 g)
Absent Absent Absent Absent Absent USP
Salmonella
(in 25 g)
Absent Absent Absent Absent Absent USP
Listeria
monocytogenes
(in 25 g)
Absent Absent Absent Absent Absent AOAC
2004.06
AOAC: Association of Official Analytical Chemists; CFU: colony forming units; Charact.: characteristic; FDA-BAM: Food and Drug
Administration’s Bacteriological Analytical Manual; ICP-MS: inductively coupled plasma mass spectrometry; MPN: most probable
number; mg/kg = parts per million; NF: novel food; USP: United States Pharmacopeia.
(a): analysed as total fibre.
(b): Residual levels of metals are tested according to a validated skip a lot testing programme.
(c): Elements by ICP-mass spectrometry (ICP-MS). Official Methods of Analysis, Method 2011.19 and 993.14, AOAC
International, (modified).
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The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of the source of the NF
The applicant identified a number of food supplements containing E. gracilis, which are marketed in
the USA, China and Japan. The most significant market share of these products appears to be in Asia,
particularly in Japan. The proposed intakes of dried E. gracilis from these products are in the range of
500 mg per day.
According to information provided by the applicant, E. gracilis also appears to be marketed as a
food ingredient (mostly in Japan) in a number of food products (e.g. Euglena bars, Euglena honey and
oat, Euglena pudding, whey protein products, Euglena smoothies, noodles with added Euglena, etc.).
When assessing E. gracilis for its suitability for the qualified presumption of safety (QPS) status, the
BIOHAZ Panel identified information on food products containing E. gracilis marketed in Japan as
cookies, cereal bars and nutritional drinks (Suzuki, 2017; EFSA BIOHAZ Panel, 2019).
3.6.2. History of the use of the NF
According to the information provided by the applicant, the NF is already sold in the USA at 500
mg/serving in the following foods: baked goods and baking mixes, beverages and beverage bases,
cereal products, dairy product analogues, milk and milk products, processed fruits and fruit juices, soft
candy, soup and soup mixes.
Table 2: Specifications of the NF
Description: The NF is the dried biomass of non-viable Euglena gracilis. The manufacturing process includes
conditions such as alkaline pH and heat treatment, which kill the microalga
Appearance: free-flowing yellow-tan powder with an odour characteristic of algae
Parameter Specification Method of analysis
Total carbohydrates (%) ≤ 75 By calculation
b-glucan (%) > 50 AOAC 991.43
Protein (%) ≥ 15 AOAC 968.06 and 992.15
Fat (%) ≤ 15 AOAC 922.06 and 954.02
Ash (%) ≤ 10 AOAC 923.03
Moisture (%) ≤ 6 AOAC 925.09 and 926.08
Heavy metals
Lead (mg/kg) ≤ 0.5 ICP-MS(a)
Cadmium (mg/kg) ≤ 0.5 ICP-MS(a)
Mercury (mg/kg) ≤ 0.05 ICP-MS(a)
Arsenic (mg/kg) ≤ 0.02 ICP-MS(a)
Microbiological
Aerobic plate count (CFU/g) ≤ 10,000 AOAC 966.23
Coliforms (MPN/g) ≤ 100 FDA-BAM
Yeast and mould (CFU/g) ≤ 500 FDA-BAM
Escherichia coli (in 10 g) Negative USP
Staphylococcus aureus (in 10 g) Negative USP
Salmonella (in 25 g) Negative USP
Listeria monocytogenes (in 25 g) Negative AOAC 2004.06
AOAC: Association of Official Analytical Chemists; CFU: colony forming units; FDA-BAM: Food and Drug Administration’s
Bacteriological Analytical Manual; ICP-MS: inductively coupled plasma mass spectrometry; MPN: most probable number; mg/kg:
parts per million; NF: novel food; USP: United States Pharmacopeia.
(a): Elements by ICP-mass spectrometry (ICP-MS). Official Methods of Analysis, Method 2011.19 and 993.14, AOAC
International, (Modified).
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3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population proposed by the applicant is the general population, except for food
supplements and for foods for total diet replacement for weight control (as defined by Regulation (EU)
609/2013) for which the target population is the general population from 12 months of age onwards.
3.7.2. Proposed uses and use levels
The applicant intends to market the NF as a food supplement, in foods for total diet replacement
for weight control (as defined by Regulation (EU) 609/2013) and as a food ingredient added to a
number of food products. The proposed use of the NF as a food ingredient with the respective food
groups and the maximum use levels of the NF therein are indicated in Table 3.
With regard to the use of the NF as a food supplement, the applicant proposed maximum daily
amounts of 100 mg/day for toddlers (i.e. from 12 to 35 months), 150 mg/day for ‘other children’ (i.e.
from 3 to 9 years), 225 mg/day for adolescents and 375 mg/day for adults.
For the use of the NF in foods for total diet replacement for weight control as defined by
Regulation (EU) 609/2013, the applicant proposed 75 mg per meal for toddlers, ‘other children’ and
adolescents, and 188 mg per meal for adults.
3.7.3. Anticipated intake of the NF
The applicant provided intake estimates for the NF based on two databases: (i) the EFSA
Comprehensive European Food Consumption Database (EFSA, 2011) and (ii) the UK National Diet and
Nutrition Survey (NDNS, 2008–2014).
As for the EFSA Comprehensive European Food Consumption Database, summary statistics of the
database were used. Mean and high level intakes of the NF were calculated, the latter ones according
to the High Exposure from Summary Statistics (HESS) model (Dempsey, 2018). The highest intake, on
a body weight basis, was calculated for infants with an anticipated intake of up to 137.6 mg/kg bw per
day for high level consumers.
Since the use of summary statistics is a known source of overestimation, the applicant performed a
second exposure assessment based on the individual data of the UK National Diet and Nutrition Survey
(NDNS, 2008–2014). The highest anticipated intake was calculated for toddlers, at 34 mg/kg bw per
day at the 95th percentile in the population of consumers (no information available on infants in this
survey).
In order to derive refined intake estimates for all the population groups under evaluation, an intake
assessment was performed by EFSA based on individual data from the EFSA Comprehensive European
Food Consumption Database (EFSA, 2011).
The food categories for the proposed uses of the NF were allocated to corresponding FoodEx2
categories of the EFSA Comprehensive Food Consumption Database as indicated in Table 4, taking into
account information provided in the application dossier (i.e. Appendix D of Annex F) plus information
provided by the applicant following a request for information.
Table 3: Proposed uses and use levels of the NF as a food ingredient
FoodEx No. Name Proposed food use
Max. use level
(mg/100 g)
A.01.000001 Grains and grain-based products Breakfast, granola and protein bars 625
A.01.000948 Milk and Dairy Products Yoghurt 150
Yoghurt Beverages 93.75
A.01.00147 Non-alcoholic beverages Fruit Juices, Smoothies and Nectars,
Vegetable Juices
117
Fruit-Flavoured Drinks 37.5
A.01.001748 Products for special nutritional use Meal replacement beverages 75
NF: novel food.
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Mean and high (i.e. 95th percentile) intake estimates were calculated for infants, young children
(i.e. toddlers), ‘other children’, adolescents, adults, elderly, very elderly, pregnant and lactating women,
assuming that the foods contain the NF at the maximum proposed use levels.
The ranges of the estimated mean and high intakes (in mg/kg bw per day) among the individual
EU dietary surveys for the various population groups are presented in Table 5. The group of adults
includes elderly, very elderly, pregnant and lactating women. The highest intake was estimated for
infants, at 100.7 mg NF/kg bw per day at the 95th percentile.
The contribution of each survey to the estimated intake for each population group is available in an
excel file annexed to the scientific opinion (under ‘Supporting information’: https://doi.org/10.2903/j.efsa.
2020.6100).
As for the intake of the NF in the form of food supplements, the proposed maximum daily doses of
the NF would correspond to intakes of 8.3, 6.5, 5.2 and 5.4 mg/kg bw per day, respectively, when
considering default body weights of 12 kg for toddlers, 23 kg for ‘other children’, 43 kg for adolescents
(mean bw of age group of 10–14 years) and 70 kg for adults (EFSA Scientific Committee, 2012).
For the intake of the NF from foods for total diet replacement for weight control (as defined by
Regulation (EU) 609/2013), assuming that the entire diet (i.e. 3 meals per day) would be replaced
with products containing the NF and considering the proposed dose of 75 mg/meal for children
(toddlers, ‘other children’ and adolescents) and 188 mg/meal for adults, this would be equivalent to a
daily NF intake of 225 mg/day for children and 564 mg/day for adults. On a body weight basis, these
daily intake levels would correspond to 18.8, 9.8, 5.2 and 8.1 mg/kg bw per day for toddlers, ‘other
children’, adolescents and adults, respectively.
3.7.4. Combined intake from the NF and other sources
The applicant did not provide a combined/cumulative intake assessment of the NF from all sources.
The reason being that foods containing the NF (i.e. food supplements or foods fortified with the NF)
will be clearly labelled, indicating the proposed maximum daily dose for the NF and a warning that
fortified foods and food supplements should not be consumed concomitantly.
No intake of the NF is expected from other sources (e.g. background diet) since there is currently
no known additional source of dried E. gracilis within the EU.
Table 4: Food categories and use levels as applied for the refined intake estimate based on the
EFSA Comprehensive Food Consumption Database
FoodEx2 code Food category Max. use level (mg/100 g)
A00EY Cereal bars 630
A02NE Yoghurt 150
A02NQ Yoghurt drinks, including sweetened and/or flavoured
variants
95
A039K Fruit and vegetable juices and nectars 120
A0EQN Soft drinks with minor amounts of fruit or flavours 40
A03RV Meal replacement beverages 75
Table 5: Refined intake estimate of the NF from foods fortified with the NF at the maximum
proposed use levels
Population groups Number of surveys
Range of means
(mg/kg bw per day)
Range of high (P95) intakes
(mg/kg bw per day)
Infants (< 12 months) 13 0.8–24.7 3.9–100.7
Toddlers (12–35 months) 16 6.1–31.6 19.7–75.3
Other children (3–9 years) 19 5.5–23.2 17.5–48.8
Adolescents (10–17 years) 20 2.8–9.4 7.2–23.6
Adults (≥ 18 years)* 22 0.9–4.7 3.3–17.2
NF: novel food; bw: body weight.
*: Includes elderly, very elderly, pregnant and lactating women.
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3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant commented that the NF is a complex ingredient that largely consists of fibre, lipids,
proteins, carbohydrates and a number of vitamins and minerals, and that the vast majority of the
constituents of the NF are normal components of the diet and would, thus, be digested and
metabolised in a way similar to usual plant matter (e.g. vegetables). The Panel considers that no
further ADME testing is necessary for the safety assessment of the NF.
3.9. Nutritional information
The applicant provided a nutritional analysis of the NF. As described in section 3.4, the NF has a
high (i.e. at least 50%) content of b-1,3-glucan. Furthermore, the NF contains protein (about 20%),
fat (about 8%), ash (about 4%) and moisture (about 4%) (means of the provided proximate analyses
of five batches of the NF). The applicant also provided information on sugar profiles and
concentrations of vitamins (C, E, D2, D3, K) and minerals, fatty acids, carotenoids and amino acids.
The Panel considers that taking into account the composition of the NF and the proposed
conditions of use the consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
3.10.1. Qualified presumption of safety (QPS)
In 2019, E. gracilis was assessed by the EFSA Panel on Biological Hazards (BIOHAZ) for its
suitability to be added to the list of QPS-recommended biological agents intentionally added to food or
feed. For this purpose, the BIOHAZ Panel considered the identity, the body of knowledge and potential
safety concerns of this microorganism. The literature searches performed did not provide any evidence
for a safety concern for human or animal health for any use of E. gracilis. The BIOHAZ
Panel concluded that E. gracilis may be recommended for the QPS list with the qualification ‘for
production purposes only’ (EFSA BIOHAZ Panel, 2019).
In June 2018, the BIOHAZ Panel clarified that the qualification ‘for production purpose only’ implies
the absence of viable cells of the production organism in the final product and can also be applied for
food and feed products based on microbial biomass (EFSA BIOHAZ Panel, 2018).
3.10.2. Genotoxicity
The applicant submitted a bacterial reverse mutation test (Product Safety Labs, 2015a) and an
in vivo micronucleus test (Product Safety Labs, 2015b). Both tests were published by Simon et al.
(2016).
The bacterial reverse mutation test (Product Safety Labs, 2015a, unpublished study report, claimed
as proprietary by the applicant) was performed in compliance with good laboratory practice (GLP) and
following OECD Test Guideline (TG) 471. The test was carried out with Salmonella Typhimurium strains
TA98, TA100, TA1535, TA1537 and Escherichia coli strain WP2uvrA in the presence or in the absence
of an exogenous metabolic activation system (i.e. S9-mix). In order to evaluate the cytotoxicity of the
test item (#040715-AM-1), a dose-finding test was performed with the five strains mentioned above,
with and without metabolic activation. There was no sign of cytotoxicity and no precipitation of the
test material was observed at any concentration tested. The main test was performed with the plate
incorporation method, while the confirmatory test was performed with the pre-incubation method.
Positive and negative controls were included. The NF induced no biologically relevant increase in the
number of revertant colonies compared with the negative controls for all strains, in the presence and
in the absence of S9-mix, up to 5,000 lg/plate.
The mammalian erythrocyte micronucleus test (Product Safety Labs, 2015b, unpublished study
report, claimed as proprietary by the applicant) was performed in compliance with GLP and following
OECD TG 474. The test was conducted in male and female Swiss albino (ICR) mice. In the preliminary
test, the NF (#040715-AM-1) was administered (by gavage) to mice (3/sex per group) at doses of 0,
500 or 2,000 mg/kg bw per day for two consecutive days. All animals survived at the end of the study
period and the highest dose tested was used in the main study. The testing results indicated no signs
of cytotoxicity in the preliminary test. In the main test, the mice (5/sex per group) were administered
the NF at doses of 0 or 2,000 mg/kg bw. Animals were dosed with the test material or negative
control on days 1 and 2. The positive control was administered on day 2 only. Blood samples were
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collected from all groups for analysis 44–48 h after treatment. For all groups, a minimum of 4,000
polychromatic erythrocytes per animal were scored for incidence of micronucleated immature
erythrocytes. No test substance related effects on reticulocyte fraction, micronucleus frequency in
normochromatic erythrocytes or frequency of micronucleated reticulocytes were observed. The
Panel notes that there was no demonstration of exposure of the test substance to the bone marrow,
and therefore, this test is considered inconclusive.
Even though an in vitro micronucleus test, as recommended in the EFSA Scientific Opinion on
genotoxicity testing strategies (EFSA Scientific Committee, 2011), was not conducted, the
Panel considers that given the nature of the NF, the production process, the QPS-status of E. gracilis
and the results of the studies presented, there are no concerns with regard to genotoxicity of the NF.
3.10.3. Acute, subacute and subchronic toxicity
The applicant submitted one acute, one subacute (14-day) and one subchronic (90-day) toxicity
study. All studies, except the 14-day study, were performed in compliance with GLP. The subacute and
subchronic toxicity studies were carried out with a lot (i.e. # 040715-AM-1) of the NF that contained
58.8% b-glucan, 26.2% protein, 6.2% fat, 4.3% moisture and 2.5% ash. The applicant submitted full
study reports for all the studies. The acute and the subchronic toxicity studies were published by
Simon et al. (2016).
The acute oral toxicity study (Product Safety Labs, 2014, unpublished study report, claimed as
proprietary by the applicant) was performed in accordance with OECD TG 402. Female nulliparous
Sprague–Dawley rats (3/group) were fasted overnight and then orally administered the NF (# 051614-
AM-1) at a dose of 5,000 mg/kg bw. All animals survived the test substance administration. There
were no signs of gross toxicity, adverse effects, or abnormal behaviour. No gross abnormalities were
noted for any of the animals when necropsied at the conclusion of the 14-day observation period.
The 14-day dietary toxicity study (Product Safety Labs, 2015c, unpublished study report, claimed as
proprietary by the applicant) was based on OECD TG 407. The study was not performed in full
compliance with GLP standards but was conducted in a GLP-compliant facility. The aim of the study
was to assess the palatability of the NF and to identify appropriate dietary levels for the 90-day
subchronic toxicity study. Sprague–Dawley rats (5/sex and group) were randomised to receive 0, 1.25,
2.5 or 5.0% of the NF (Lot #: 040715-AM-1) in the diet. There were no mortalities during the study
period. As there were no changes on bodyweight, bodyweight gain, food consumption or food
efficiency, it was concluded that the animals are expected to tolerate at least 5% (i.e. 50,000 mg/kg
feed) of the NF in the diet.
The 90-day oral toxicity study (Product Safety Labs, 2015d, unpublished study report, claimed as
proprietary by the applicant) was conducted in accordance with OECD TG 408.
Sprague–Dawley rats (10/sex and group) of 7-8 weeks of age were randomly distributed to receive
0, 1.25, 2.5 or 5.0% of the NF (Lot #: 040715-AM-1) in the diet. All animals survived to the end of the
study period. There were no findings with respect to clinical observations, ophthalmology and
behavioural analysis of the animals. There were no relevant differences in body weight or body weight
gain, food consumption or food efficiency. No changes were found for macroscopic and microscopic
observations.
No changes were seen in haematology (including blood coagulation tests) except for haematocrit,
for which a statistically significant decrease was found in males in the mid-dose group only (without
dose response relationship). In clinical chemistry, the only statistically significant difference observed
was a decrease of serum aspartate aminotransferase (AST) in males in the high-dose group. No
effects were observed for parameters of urinalysis. Concerning organ weights, the only observations
were reduced weights (statistically significant) of adrenal glands and epididymis in males in the low-
dose group. The Panel considers these findings as incidental.
Based on the results, the Panel considers as the no observed adverse effect level (NOAEL) the
highest dose (i.e. 5%) tested in the study, equivalent to 3,300 mg NF/kg body weight per day.
3.11. Allergenicity
The Panel notes the protein content of about 20% in the NF and, therefore, the potential of the NF
to elicit allergic reactions.
A comprehensive literature search performed by the applicant did not reveal any studies or case
reports raising potential concerns on the allergenicity of E. gracilis. The applicant also pointed out the
history of use of E. gracilis in Japan and the US and the lack of identified allergenic reactions so far.
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The Panel considers that the risk of allergic reactions to the NF for the general population is
unknown but expected to be low.
4. Discussion
The NF, which is the subject of the application, is the dried biomass of Euglena gracilis. The
Panel considers that the information provided on the composition of the NF is sufficient and does not
raise safety concerns.
In 2019, E. gracilis was assessed by the EFSA BIOHAZ Panel and attributed the QPS status with the
qualification ‘for production purposes’, which implies the absence of viable Euglena cells in the final
product and can also be applied for food products based on microbial biomass of the microalgae.
The Panel considers that based on the information provided, the microalga is not expected to
survive the manufacturing process and thus, the production process does not raise safety concerns.
The applicant intends to market the NF as a food supplement, in foods for total diet replacement
for weight control and as a food ingredient added to a number of food products. The target population
proposed by the applicant is the general population, except for food supplements and for foods for
total diet replacement for which the target population is the general population from 12 months of age
onwards.
Intake estimates for the NF consumed via foods fortified with the NF were performed for all
population groups, based on the EFSA Comprehensive European Food Consumption Database. The
highest intake estimate was calculated for infants, at 100.7 mg NF/kg bw per day at the 95th
percentile.
The submitted toxicity studies did not raise safety concerns. No adverse effects were observed in
the subchronic study, up to the highest dose tested, i.e. 3,300 mg NF/kg body weight per day, which
the Panel considers as the NOAEL of the study.
The margins of exposure between the NOAEL of 3,300 mg/kg bw per day, the highest dose tested,
and the high (95th percentile) intake estimates, range from 33 (infants) to 192 (adults).
The Panel considers that in view of the QPS status of the source of the NF, supported by the
compositional data and lack of toxicity in the experimental studies, the margins of exposure are
sufficient.
5. Conclusions
The Panel considers that the NF, i.e. dried whole cell Euglena gracilis, is safe at the proposed uses
and use levels.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the full study-report of the 90-day toxicity study (Product Safety Labs,
2015d) for which protection of proprietary data was requested by the applicant.
6. Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of dried whole cell Euglena. Ref. Ares(2019)
3149232, dated 13/05/2019.
2) On 13 May 2019, a valid application on dried whole cell Euglena, which was submitted by
Kemin Foods L.C., was made available to EFSA by the European Commission through the
Commission e-submission portal (NF 2018/0669) and the scientific evaluation started.
3) On 18 July 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 18 September 2019, additional information was provided by the applicant and the
scientific evaluation was restarted.
5) During its meeting on 25 March 2020, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of dried whole cell Euglena gracilis as a NF pursuant to
Regulation (EU) 2015/2283.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
AOAC Association of Official Analytical Chemists
AST aspartate aminotransferase
ATCC American Type Culture Collection
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BIOHAZ Biological Hazards
bw body weight
CFU colony forming units
cGMP current good manufacturing practices
Charact characteristic
FDA-BAM Food and Drug Administration’s Bacteriological Analytical Manual
GLP good laboratory practice
HACCP hazard analysis critical control points
HESS High Exposure from Summary Statistics
ICP-MS inductively coupled plasma mass spectrometry
LOD limit of detection
MPN Most probable number
NDNS National Diet and Nutrition Survey
NMR nuclear magnetic resonance
NOAEL no observed adverse effect level
NF novel food
OECD Organisation for Economic Co-operation and Development
PAH polycyclic aromatic hydrocarbons
PCR polymerase chain reaction
QPS qualified presumption of safety
USP United States Pharmacopeia
WCE whole cell Euglena
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